Last reviewed · How we verify

AZD5153 — Competitive Intelligence Brief

AZD5153 (AZD5153) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BET bromodomain inhibitor. Area: Oncology.

phase 1 BET bromodomain inhibitor BET bromodomain Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD5153 (AZD5153) — Acerta Pharma BV. AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD5153 TARGET AZD5153 Acerta Pharma BV phase 1 BET bromodomain inhibitor BET bromodomain

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BET bromodomain inhibitor class)

  1. Acerta Pharma BV · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD5153 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd5153. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: